Open 15-Minute Strategy Calls: Limited Weekly Slots Book yours →
Level of care · MAT

MAT clinic marketing: accurate, local, and stigma-aware

Medication-assisted treatment is evidence-based medicine that still fights a stigma problem. Marketing it well means being medically accurate, radically clear, and easy to find at the moment someone decides they're ready, without a hint of the shame the condition already carries.

Vincent Bocassi, Jordon Wallen, and Sean Meigh discussing a regulated-market strategy in the IDK Strategies office
Vinny, Jordon, and Sean working through the details that regulated-market growth demands.

The MAT marketing problem is a trust problem

Methadone, buprenorphine, and naltrexone are recommended standards of care for opioid use disorder, and many people still believe they're "trading one addiction for another." That gap between evidence and perception is the whole marketing challenge. Content that plainly explains how MAT works, what each medication does, and what a day in treatment looks like removes the fear that keeps people from calling. This is treatment SEO in its most educational form.

Meet high-intent, low-shame search

  • Medication

    Medication searches

    High-intent, local, often private, local pack and honest medication pages win.

  • Questions

    Question searches

    Accurate answers capture research intent almost no competitor addresses well.

  • Access

    Access searches

    Same-day and walk-in intent, a real differentiator when you answer fast.

Three high-intent, low-shame search moments, each won with honest, accurate pages.

Accuracy is a compliance requirement, not a style choice

MAT marketing lives under the same restricted-advertising rules as the rest of the category, LegitScript certification for Google and Meta, HIPAA and 42 CFR Part 2 for communications, plus the extra weight of making medical claims. Overstated success rates or vague medical language aren't just risky, they undermine the credibility MAT marketing depends on. We keep claims defensible and let the honesty do the persuading.

Retention is the real metric

MAT outcomes depend on staying in treatment, and drop-off is the industry's hardest problem. Marketing doesn't stop at the first visit: appointment reminders, refill nudges, and re-engagement for missed visits, all through compliant, consent-based SMS in the pipeline, protect both outcomes and program revenue. A patient who stays is a life changed and a census held.

Reach the people around the patient

Family members, primary care physicians, and emergency departments all refer to MAT. Content and relationships aimed at referrers, "how to find a Suboxone doctor for a family member," clear clinician-facing referral information, widen the funnel beyond direct search, the same way outpatient programs build step-down referral flows.

A working style guide for stigma-aware copy

Everything above argues that MAT marketing is a trust exercise. Here is the layer underneath: the actual words. Language isn't a soft consideration in this category, it's the mechanism a reader uses to decide, in seconds, whether you see them as a patient or as a problem. Studies with clinicians have found that describing someone as a "substance abuser" rather than a "person with a substance use disorder" nudges even trained professionals toward blame and punishment. Your reader is not a trained professional. They're someone at one in the morning deciding whether a form is safe to fill out. Every word either lowers the wall or adds a brick.

A handful of principles do most of the work. Person-first language keeps the human ahead of the condition. Clinical framing keeps moral judgment out of medical facts. And precision beats euphemism, vague language reads as embarrassment, and embarrassment confirms the reader's fear that this is something to be ashamed of.

Common phrasingStigma-aware alternativeWhy it matters
Addict, abuser, userPerson with opioid use disorder; person in treatmentPerson-first language separates the person from the condition. A label collapses a whole human into a diagnosis, and readers feel it instantly.
Clean / dirtyNegative / positive (test results); in recovery"Dirty" turns a lab value into a moral verdict. Describing results clinically signals you'll treat the person clinically too.
Opioid replacement / substitutionMedication for opioid use disorder; medication-assisted treatment"Replacement" restates the exact myth that keeps people away, that MAT swaps one addiction for another.
Drug habitOpioid use disorder"Habit" implies a choice someone should simply stop making. Naming a medical condition makes a medical treatment feel sensible, not weak.
Get clean, kick the habitStart treatment; begin recoveryRecovery framed as hygiene implies the person is currently dirty. A beginning respects how people actually experience it.
We can cure your addictionEvidence-based care that supports long-term recoveryCure claims are clinically wrong and a compliance liability, and honest framing persuades a reader who has heard big promises before.

Show it, don't just say it

Imagery carries as much stigma as words. Skip the stock-photo vocabulary of despair, scattered pills, needles, a silhouette against a rain-streaked window. Those images tell a visitor you see them at their worst moment. Show what the person will actually encounter: a reception desk, a consult room, staff who look at the camera, daylight. Ordinary is the point. Someone choosing a MAT clinic is choosing to make treatment part of a normal week, and your visuals should make that feel plausible.

Microcopy deserves the same care. A button that says "Talk with our team" makes a different promise than one shouting "GET HELP NOW." Put a one-sentence confidentiality note beside every form, who sees the submission, and how it's protected. And drop urgency mechanics like countdown timers entirely; pressure reads very differently when the decision is disclosing a substance use disorder.

42 CFR Part 2: the privacy bar sits higher than HIPAA

Most healthcare marketers know HIPAA. Fewer know that substance use treatment records carry a second, older, stricter layer of federal protection. 42 CFR Part 2 governs records held by federally assisted substance use disorder programs, which covers most MAT clinics and every opioid treatment program, and the protected fact includes the most basic one there is: that a person is a patient at all. Rulemaking in recent years has pulled Part 2 closer to HIPAA on consent and enforcement, but that core principle hasn't moved. Patienthood itself is confidential.

That reshapes marketing habits that are routine elsewhere in healthcare:

The one-question campaign test

Before anything ships, ask: could this reveal to anyone that a specific person has received substance use treatment? Not "is it likely", could it. If the answer is yes, or even maybe, redesign until the answer is a clean no. Every practice in this section falls out of that single question.

The intents the basic map misses: cost, comparison, logistics

Medication, question, and access searches, covered above, are the core of MAT demand. Three quieter clusters decide almost as many admissions, and almost nobody builds content for them.

Cost and coverage searches

Money questions arrive wrapped in medication names: whether Medicaid covers a given medication, what treatment costs without insurance, whether you take a specific plan. Cost anxiety is one of the most common reasons people delay care, and most clinic websites answer it with a phone number and a shrug. Publish the plain version: the plans you accept, how verification works and how long it takes, what self-pay looks like at your clinic, and any sliding-scale arrangements you genuinely offer. You don't need a price list to be useful, you need to remove the fear that the number is unspeakable. And if you run an insurance-verification form, apply the privacy rules above to every field of it; that form is patient-adjacent data from the moment it's submitted.

Comparison searches

People weighing treatment compare options by name, one medication against another, daily dosing against long-acting formulations, clinic-based care against telehealth. The single biggest of these is methadone vs Suboxone. These searches deserve clinician-reviewed pages that lay out real trade-offs, with a named medical reviewer and a visible review date. Write them honestly even where honesty points away from your own service line; a reader who catches you steering will not call, and a reader who sees you being fair often will. In a category this consequential, the comparison page is where search engines and humans alike judge whether your expertise is real.

Logistics and life-on-MAT searches

Transfers between clinics, guest dosing while traveling, take-home policies, what to bring to a first appointment, your front desk answers these daily, and current patients search them as often as prospective ones. Publishing policy-level answers serves both audiences and quietly supports retention. Draw one firm line: policies and processes belong on the website; clinical questions about dosing, interactions, or tapering belong with clinicians. A sentence routing those questions to your medical team is both safer and more reassuring than an answer that shouldn't be there.

Jarrod Wentworth and Eric Friedman coordinating intake follow-up in the IDK Strategies office
Respect continues through the handoff: a clear next step, a real response, and no patient left wondering.

Telehealth MAT: earning trust through a screen

Telehealth changed who can realistically start MAT, rural patients, shift workers, parents without childcare, people who can't risk being seen in a waiting room. It also inherited skepticism from two directions at once: patients worry an online prescriber is a scam, and regulators worry it's a mill. Your positioning has to answer both, and in both cases the answer is specificity.

Name your clinicians, with credentials and the states they're licensed in. Walk through the visit flow step by step, what the first appointment covers, how prescriptions reach a local pharmacy, how follow-ups and screening work, what happens if someone needs a higher level of care. Be honest about boundaries: methadone is dispensed through opioid treatment programs, so telehealth MAT is largely a buprenorphine story, and saying so plainly signals you know the medicine. Vague pages that could describe any telehealth service read, to a wary patient, exactly like the mills they fear.

Two structural notes. First, the rules for prescribing controlled substances via telehealth have shifted several times in recent years and may shift again, date-stamp your telehealth pages, review them on a schedule, and never let a claim outlive the rule it described. Second, resist faking a local footprint. A telehealth program has no business creating map listings for virtual offices; they get suspended, and they're dishonest in a category where honesty is the product. Build state-level pages that reflect your actual licensure instead. And remember the telehealth shopper compares several providers in one sitting, being first with a substantive answer often decides it, which is exactly the gap a HIPAA-conscious AI admissions agent was built to close.

Build the referral network like a second growth channel

Search captures people who are looking. Referral development reaches people at the moment someone else is looking on their behalf, an emergency physician at discharge, a probation officer at intake, a primary care doctor who screens for opioid use disorder but doesn't prescribe for it. For many MAT programs this channel is worth as much as search, and it's built on fundamentals rather than budget.

Start by mapping who touches your future patients: emergency departments, especially those with bridge-prescribing programs that start buprenorphine and need a community handoff, hospital discharge planners, primary care practices, federally qualified health centers, drug courts and probation offices, pharmacists, and the step-down pipeline of detox programs and residential facilities whose patients need ongoing medication support after discharge. Don't overlook sober living operators: many homes still refuse residents on MAT, so the ones that welcome them are natural, motivated partners.

Then make referring to you the easiest option on their list:

One bright line: never pay for referrals. Federal law, including the Eliminating Kickbacks in Recovery Act, prohibits paying for patient referrals in this field, and any arrangement priced per patient should end the conversation. The durable network is built on being genuinely easy to work with, not on inducements.

The paid landscape for MAT terms

Advertising MAT means clearing two policy layers at once. The first is the addiction-treatment gate: Google and Meta require LegitScript certification before treatment providers can advertise at all, and Microsoft Advertising maintains its own certification requirement for the category. If you haven't started, the certification process runs on a timeline of weeks, not days, begin before you need the traffic.

The second layer surprises people: pharmaceutical policy. Ad copy that names prescription medications can trip drug-related rules even inside a certified account, producing disapprovals that look random but aren't. The reliable pattern is to name the condition and the care model in the ad, medication-assisted treatment, opioid use disorder care, same-day starts, and let the landing page carry the medication-specific detail. The landing page is part of the review too: licensure, a real address, working contact information, and claims discipline throughout.

Measure the program, not the patient

Federal regulators have warned that everyday web-tracking tools, running on pages about health conditions, can amount to disclosures of protected information. For a MAT program the implication is blunt: treat every visitor to your treatment pages as a possible future patient, because that's what they are. The measurement question is never "what can we track", it's "what can we learn without ever knowing who someone is."

The architecture follows from that. Keep third-party pixels off condition and treatment pages unless they sit behind the right agreements and a deliberate configuration review. Route calls through tracking that operates under a business associate agreement. Send form submissions into a CRM configured for treatment programs, inside your compliance perimeter, rather than letting an ad platform become your database. When platforms need conversion signals to optimize, send the least data necessary: a conversion event stripped of health context is a design goal, not a limitation.

Then report in aggregate, because aggregate is all a marketing decision ever needs. Inquiries by channel. The share that verify insurance. Show rate for first appointments. Retention at thirty and ninety days, sliced by how the patient first found you, the cut that reveals whether a channel brings people who stay, which for MAT is the number that matters most. Every one of those is a count, and no one in a marketing meeting ever needs to see a name.

A final word on patience. At the volumes a single clinic produces, channel-level signals firm up over weeks, not days, and the temptation is to bolt on more invasive tracking to speed the answer. Resist it. The programs that win this category play the long game on trust, in their copy, their privacy posture, and their measurement. For the fuller operating manual, start with the free Admissions Playbook, or bring us your medication pages and we'll tell you plainly what we'd fix first.

Frequently asked questions

Can we name Suboxone or methadone in our ads?

Often not directly, ad copy naming prescription medications can trigger pharmaceutical-policy disapprovals even in a LegitScript-certified account. The dependable pattern is to name the condition and care model in the ad and keep medication specifics on the landing page. Organic search is a different story: detailed, accurate medication pages are fair game, and essential.

Do patient testimonials violate 42 CFR Part 2?

They can. Disclosing that someone was a patient requires specific written consent under Part 2, a generic media release doesn't cover it. Even with valid consent, weigh whether a permanent public disclosure genuinely serves the former patient. Staff perspectives, program-level facts, and genuinely useful educational content persuade without spending anyone's privacy.

Can our marketing agency or CRM vendor see patient information?

Only under the right agreements, typically a business associate agreement, a qualified service organization agreement, or both, and even then only the minimum needed to do the job. Anyone touching form submissions, call recordings, or your CRM sits inside that perimeter. A vendor who waves off the paperwork is telling you something important.

Does local SEO matter for telehealth-only MAT?

It matters differently. A telehealth program shouldn't create map listings for virtual offices, they violate platform rules and get suspended. Build state-level pages that reflect your actual licensure and let educational content capture online-prescriber searches. Hybrid programs get both: a legitimate local presence for the clinic, plus state pages for the telehealth arm.

Related guides

Service

Addiction treatment SEO

Educational, medically accurate content that ranks.

Service

SMS marketing and A2P compliance

The retention layer MAT outcomes depend on.

Level of care

PHP and IOP marketing

Outpatient care that often runs alongside MAT.

Flagship

Rehab admissions automation

Answer access-intent inquiries the moment they arrive.

Market MAT the way the medicine deserves

We'll review your medication pages, local presence, and retention communication, and build a plan that grows the program while it fights the stigma.

Grow my MAT program
Call Book a strategy call